Management of hepatic encephalopathy: Role of rifaximin

Chemotherapy

Volumn 51, Issue SUPPL. 1, 2005, Pages 90-95

  Zeneroli, Maria Luisa ^a   Avallone, Rossella ^a   Corsi, B Lorenzo ^a   Venturini, Ivo ^a   Baraldi, Claudia ^a   Baraldi, Mario ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Ammonia; Bacterial flora; Benzodiazepines, endogenous; Encephalopathy, hepatic; Liver cirrhosis; Rifaximin

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMMONIA; BENZODIAZEPINE DERIVATIVE; LACTULOSE; NEOMYCIN; PAROMOMYCIN; RIFAXIMIN; SORBITOL;

AMMONIA BLOOD LEVEL; AMMONIA FORMATION; BACTERIAL FLORA; BRAIN FUNCTION; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; GABAERGIC SYSTEM; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PATIENT MONITORING; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW;

AMMONIA; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIDEPRESSIVE AGENTS; BACTERIA; BENZODIAZEPINES; CLINICAL TRIALS; HEPATIC ENCEPHALOPATHY; HUMANS; INTESTINAL ABSORPTION; INTESTINES; RIFAMYCINS;

EID: 18644374526     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081994     Document Type: Review

References (62)

1. Conn HO, Bircher J: Hepatic Encephalopathy: Syndromes and Therapies. Bloomington, Medi-Ed Press, 1994.
2. Avallone R, Zeneroli ML, Venturini I, Corsi L, Schreier P, Kleinschnitz M, Ferrarese C, Farina F, Baraldi C, Pecora N, Frigo M, Baraldi M: Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of liver cirrhosis patients with and without encephalopathy. Gut 1998;42:860-867.
3. Zeneroli ML, Ventura E, Baraldi M, Penne A, Messori E, Zieve L: Visual evoked potentials in encephalopathy induced by galactosamine, ammonia, dimethyldisulfide and octanoic acid. Hepatology 1982;2:532-538.
4. Baraldi M, Pinelli G, Ricci P, Zeneroli ML: Toxins in hepatic encephalopathy: The role of the synergistic effect of ammonia, mercaptans and short chain fatty acids. Arch Toxicol 1984;7:103-105.
5. Wang V, Saab S: Ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003;114:237-238.
6. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, Arroliga AC, Mullen KD: Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003;114:188-193.
7. Moroni F, Lombardi G, Moneti G, Cortesini C: The release and neosynthesis of glutamic acid are increased in experimental models of hepatic encephalopathy. J Neurochem 1983;40:850-854.
8. Ferenci P, Pappas SC, Munson PJ, Jones AE: Changes in glutamate receptors on synaptic membranes associated with hepatic encephalopathy or hyperammonemia in the rabbit. Hepatology 1984;4:25-29.
9. Butterworth RF, Lavoie J, Peterson C, Cotman CW, Szerb J: Excitatory amino acids and hepatic encephalopathy; in Pomier Larargue G, Butterworth RF (eds): Hepatic Encephalopathy: Pathophysiology and Treatment. Clifton, Humana Press, 1989, pp 417-433.
10. Baraldi M: Supersensitivity of GABA-A receptors in hepatic encephalopathy. Neurochem Res 1990;15:153-160.
11. Norenberg MD, Itzhak Y, Bender S: The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. Adv Exp Med Biol 1997;420:95-111.
12. Zanoli P, Giacobazzi A, Vaccari G, Zeneroli ML, Baraldi M: Up-regulation of peripheral benzodiazepine receptors in brain areas of rats with galactosamine-induced hepatic encephalopathy; in Bengtsson F, Jeppson B (eds): Progress in Hepatic Encephalopathy. Miami, CRC Press, 1991, pp 161-168.
13. Lavoie J, Pomier Layrargues G, Butterworth RF: Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 1990;11:874-882.
14. Baraldi M, Zeneroli ML: Experimental hepatic encephalopathy: Changes in the binding of gamma-aminobutyric acid. Science 1982;216:427-429.
15. Basile AS, Gammal SH, Jones EA, Skolnick P: GABA-A receptor complex in an experimental model of hepatic encephalopathy: Evidence for elevated levels of an endogenous benzodiazepine receptor complex ligand. J Neurochem 1989;53:1057-1063.
16. Baraldi M, Guidotti A, Schwartz JP, Costa E: GABA receptors in clonal cell lines: A model for study of benzodiazepine action at molecular level. Science 1979;205:821-823.
17. Schafer DF, Jones EA: Hepatic encephalopathy and the gamma-aminobutyric- acid neurotransmitter system. Lancet 1982;ii:18-20.
18. Zeneroli ML, Iuliano E, Racagni C, Baraldi M: Metabolism of gamma-aminobutyric acid and brain uptake in galactosamine induced hepatic encephalopathy. J Neurochem 1982;33:1219-1222.
19. Zeneroli ML, Baraldi M, Ventura E, Vezzelli C, Tofanetti O, Germini M, Casciarri I: Alterations of GABA-A and dopamine D2 brain receptors in dogs with portal-systemic encephalopathy. Life Sci 1991;48:37-50.
20. Baraldi M, Zeneroli ML, Ventura E, Penne A, Pinelli G, Ricci P, Santi M: Supersensitivity of benzodiazepine receptor in hepatic encephalopathy due to fulminant hepatic failure in the rat: Reversal by a benzodiazepine antagonist. Clin Sci 1984;67:167-175.
21. MacDonald GA, Frey KA, Agranoff BW, Minoshima S, Koeppe RA, Kuhl DE, Shulkin BL, Lucey MR: Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy. Hepatology 1998;26:277-282.
22. 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry 1999;156:952-954.
23. Branch RA, Morgan MH, James J, Read AE: Intravenous administration of diazepam in patients with chronic liver disease. Gut 1976;17:975-983.
24. Bakti G, Fisch HU, Karlaganis G, Bircher J: Mechanism of the excessive sedative response of cirrhotics to benzodiazepine: Model experiments with triazolam. Hepatology 1987;7:629-638.
25. Wildmann J, Vetter W, Ranadaler UB, Schmidt K, Maurer R, Möhler H: Occurrence of pharmacologically active BZD in trace amounts in wheat and potato. Biochem Pharmacol 1988;37:3549-3559.
26. Medina JH, Pena C, Levi de Stein M, Wolfman C, Paladini AC: Benzodiazepine-like molecules as well as other ligands for the brain benzodiazepine receptors are relatively common constituents of plants. Biochem Biophys Res Commun 1989;165:547-553.
27. Avallone R, Zanoli P, Corsi L, Cannazza G, Baraldi M: Benzodiazepine-like compounds and GABA in flower heads of Matricaria chamomilla. Phytother Res 1996;10:177-179.
28. Avallone R, Corsi L, Zanoli P, Di Bella M, Monzani A, Venturini I, Zeneroli ML, Baraldi M: Sostanze ad attività benzodiazepino-simili in alimenti e in droghe vegetali: implicazioni fisiologiche e patologiche. Acta Phytother 1997;3:42-50.
29. Sangameswaran L, De Blas AL: Demonstration of the benzodiazepine-like molecules in the mammalian brain with a monoclonal antibody to benzodiazepines. Proc Natl Acad Sci USA 1985;82:5560-5564.
30. De Blas AL, Park D, Friedrich P: Endogenous benzodiazepine-like molecules in human, rat and bovine brains studied with a monoclonal antibody to benzodiazepines. Brain Res 1987;413:275-284.
31. Unseld E, Klotz U: Benzodiazepines: Are they of natural origin? Pharmacol Res 1989;6:1-3.
32. Olasmaa M, Rothstein JD, Guidotti A, Weber PJ, Paul SM, Spector S, Zeneroli ML, Baraldi M, Costa E: Endogenous benzodiazepine in human and animal hepatic encephalopathy. J Neurochem 1990;55:2015-2023.
33. Rothstein JD: Benzodiazepine-receptor ligands and hepatic encephalopathy: A causal relationship? Hepatology 1994;19:248-250.
34. Leimgruber W, Batcho AD, Schenker F: The structure of anthramycin. J Am Chem Soc 1965;87:5793-5795.
35. Luckner M, Nover L: Biosynthesis of the benzodiazepine and quinoline alkaloids of Penicilium cyclopium and Penicillum viridatum; in Mothes K, Kurt H (eds): Biochemistry: Physiology of Alkaloids. 4th Int Symp. Berlin, Akademie Verlag, 1969, pp 525-533.
36. Yurdaydin C, Walsh TJ, Howard DE, Ha J, Li Y, Jones EA, Basile AS: Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Res 1995;679:42-48.
37. Avallone R, Corsi L, Zeneroli ML, Baraldi M: Presence of benzodiazepine-like molecules in food and their implication in the nutrition of cirrhotic patients. Inn Food Sci Technol 2001;23:193-198.
38. Basile AS, Harrison PM, Hughes RD, Gu ZQ, Pannell L, McKinney A, Jones EA, Williams R: Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994;19:112-121.
39. Zeneroli ML, Venturini I, Stefanelli S, Farina F, Cosenza R, Miglioli L, Minelli E, Amedei R, Ferrieri A, Avallone R, Baraldi M: Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis. Pharmacol Res 1997;35:557-560.
40. Del Piccolo F, Amodio P, Mapelli D, Montagnese S, Pellegrini A, Valenti P, Ferrieri A, Gatta A: Rifaximin reduces EEG relative beta power in patients with minimal hepatic encephalopathy: Preliminary findings; in Jones EA, Mejer AJ, Chamuleau RAFM (eds): Encephalopathy and Nitrogen Metabolism in Liver Failure. Dordrecht, Kluwer Academic Publishers, 2003, chap 35, pp 361-367.
41. Bircher J, Muller J, Guggenheim P, Haemmerli UP: Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet 1966;1:890-892.
42. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72:573-583.
43. Lanthier PL, Morgan MY: Lactitol in the treatment of chronic hepatic encephalopathy: An open comparison with lactulose. Gut 1985;26:415-420.
44. Parini P, Cipolla A, Ronchi M, Salzetta A, Mazzella G, Roda E: Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992;52:34-39.
45. Morgan MH, Read AE, Speller DCE: Treatment of hepatic encephalopathy with metronidazole. Gut 1982;23:1-7.
46. Tarao K, Ikeda T, Hayashi K, Sakurai I: A Successful use of vancomycin hydrochloride in the treatment of lactulose-resistant chronic hepatic encephalopathy. J Gastroenterol Hepatol 1989;4:284-286.
47. Berk DP, Chalmers T: Deafness complicating antibiotic therapy of hepatic encephalopathy. Ann Intern Med 1970;73:393-396.
48. Gillis JC, Brogden RN: Rifaximin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-484.
49. De Marco F, Santamaria Amato P, D'Arienzo A: Rifaximin in collateral treatment of portal-systemic encephalopathy: A preliminary report. Curr Ther Res 1984;36:668-674.
50. Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, Celle G: A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11:387-392.
51. Di Piazza S, Filippazzo GM, Valenza LM, Morello S, Pastore L, Conti A, Cottone S, Pagliaro L: Rifaximin versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991;23:403-407.
52. Pedretti G, Calzetti C, Missale G, Fiaccadori F: Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991;23:175-178.
53. Festi D, Mazzella G, Parini P, Ronchi M, Cipolla A, Orsini M, Sangermano A, Bazzoli F, Aldini R, Roda E: Treatment of hepatic encephalopathy with non-absorbable antibiotics. Ital J Gastroenterol 1992;24:14-16.
54. Massa MD, Vallerino MD, Dodero MD: Treatment of hepatic encephalopathy with rifaximin: Double blind, double dummy study versus lactulose. Eur J Clin Res 1993;4:7-18.
55. Fera G, Agostinacchio F, Nigro M, Schiraldi O, Ferrieri A: Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993;4:57-66.
56. Bucci L, Palmieri GC: Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118.
57. Puxeddu A, Quartini M, Massimetti A, Ferrieri A: Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995;13:274-281.
58. Miglio F, Valpiani D, Rossellini SR, Ferrieri A: Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997;13:593-601.
59. Williams R, James OF, Warnes TW, Morgan MY: Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: A double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000;12:203-208.
60. Lata J, Hulek P, Fejfar T, Spicak J, Drastich P, Marecek Z, Bruha R, Husova L, Senkyrik M: Rifaximin in the treatment of hepatic encephalopathy. Vnitr Lek 2002;6:578-582.
61. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C: Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Minerva Gastroenterol Dietol 2003;49:53-62
62. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodriguez-Martinez D, Fernandez-Rodriguez C, Coll I, Pardo A: Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:51-58.